Details of the Drug Reposition

General Information of This Drug (ID: DMZ3P6C)

Drug Name
Teplizumab   DMZ3P6C
Drug Type
Antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
1 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Type-1 diabetes DIS7HLUB 5A10 Approved [1]
------------------------------------------------------------------------------------
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Melanoma DIS1RRCY 2C30 Phase 3 [2]
------------------------------------------------------------------------------------

References

1 FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761183.
2 ClinicalTrials.gov (NCT00920582) Protege Encore Study- Clinical Trial of Teplizumab (MGA031) in Children and Adults With Recent-Onset Type 1 Diabetes Mellitus. U.S. National Institutes of Health.